Quince Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-84.0M | $-56.8M | $-31.4M | $-51.7M | $-89.9M | $-76.8M | $-37.0M | $-12.5M |
| Depreciation & Amortization | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K | $332.0K | $188.0K | $51.0K |
| Depreciation | $100.0K | $200.0K | $300.0K | $200.0K | $344.0K | $332.0K | $188.0K | $51.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $5.1M | $4.7M | $5.2M | $16.6M | $29.9M | $14.5M | $2.1M | $155.0K |
| Net Cash from Operating Activities | $-41.4M | $-31.9M | $-18.3M | $-44.0M | $-62.9M | $-50.8M | $-33.3M | $-11.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $23.2M | $21.9M | $-5.8M | $18.0M | $59.0M | $-52.4M | $-17.7M | $-46.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $17.9M | $-4.8M | $143.0K | $707.0K | $6.8M | $118.9M | $77.4M | $75.9M |
| Net Change in Cash | $-403.0K | $-14.5M | $-23.8M | $-25.1M | $2.9M | $15.6M | $26.3M | — |
| Free Cash Flow | $-41.8M | $-32.2M | $-18.5M | $-44.2M | $-63.1M | $-50.9M | $-33.3M | $-11.9M |